Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
August 21st, 2019
9.7K views
A detailed method is provided here describing the purification, refolding, and characterization of self-assembling protein nanoparticles (SAPNs) for use in vaccine development.
Overview
This article details a method for the purification, refolding, and characterization of self-assembling protein nanoparticles (SAPNs) aimed at vaccine development. The described technique allows for the presentation of trimeric antigens in a native-like conformation.
Key Study Components
Area of Science
- Biotechnology
- Vaccine Development
- Protein Engineering
Background
- Self-assembling protein nanoparticles (SAPNs) are promising for vaccine applications.
- The method can be adapted for various SAPN constructs.
- Large-scale production is feasible for clinical trials.
Purpose of Study
- To provide a detailed protocol for SAPN purification and characterization.
- To facilitate the development of effective vaccines against infectious diseases.
- To enable the assessment of protein purity and functionality.
Methods Used
- Sonication and centrifugation for cell lysis.
- FPLC for protein purification.
- SDS-PAGE for assessing protein purity.
- Dialysis for refolding SAPNs.
Main Results
- Successful purification of six-helix bundle SAPNs.
- Refolding of proteins to achieve native-like conformations.
- Characterization of protein purity through gel electrophoresis.
- Adaptability of the method for other SAPN constructs.
Conclusions
- The method provides a reliable approach for SAPN production.
- It supports the development of vaccines with trimeric antigens.
- Future applications may include large-scale clinical production.
Frequently Asked Questions
What are self-assembling protein nanoparticles?
Self-assembling protein nanoparticles (SAPNs) are engineered proteins that can form stable nanoparticle structures suitable for vaccine development.
How can this method be applied to other constructs?
With slight modifications, the purification and refolding method can be adapted for various SAPN vaccine constructs.
What is the significance of using trimeric antigens?
Trimeric antigens can enhance the immune response by mimicking the natural structure of pathogens.
What role does FPLC play in this method?
FPLC is used for the purification of proteins, allowing for the isolation of the desired SAPNs from other cellular components.
How is protein purity assessed in this study?
Protein purity is assessed using SDS-PAGE, which allows visualization of protein bands and determination of their sizes.
What are the storage conditions for purified SAPNs?
Purified SAPNs should be stored under conditions that maintain their stability, typically at low temperatures and in appropriate buffers.
Executive Industry Relevance
Self-assembling protein nanoparticles (SAPNs) enable trimeric antigen presentation for vaccine development, addressing the need for structurally authentic immunogens in early discovery. The E. coli-based production system offers a scalable, cost-effective platform for generating vaccine candidates with reduced endotoxin contamination. This approach supports mechanistic de-risking by validating antigen conformation and purity before advancing to preclinical evaluation.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of trimeric epitope presentation and structural fidelity of vaccine antigens.
- Operational Value: Uses E. coli expression to rapidly produce SAPN monomers for functional assessment.
- Predictive Value: Confirms antigenicity via Western blot with monoclonal antibodies, supporting target validation decisions.
Screening & Assay Development
- Scientific Value: Generates homogeneous SAPN particles (20–100 nm) suitable for standardized antigen display assays.
- Operational Value: Employs DLS, NTA, and TEM for quantitative size and polydispersity measurements, enabling assay reproducibility.
- Platform Value: Facilitates preparation of validated nanoparticle libraries for high-throughput epitope screening.
Translational & Preclinical Research
- Scientific Value: Demonstrates refolding competence and particle assembly under controlled buffer conditions, critical for translational consistency.
- Operational Value: Includes isopropanol wash to reduce LPS, improving safety profile for downstream immunogenicity testing.
- Predictive Value: Confirms multimer formation and antigen accessibility, supporting go/no-go decisions for preclinical models.
Pipeline & Workflow Integration
The method integrates into the vaccine discovery continuum from antigen design through lead identification, enabling iterative refinement of trimeric display systems.
- Discovery Biology: Supports hypothesis testing on antigen conformation and oligomerization state via FPLC purification and Western blot.
- Screening: Produces monodisperse SAPN preparations for reliable binding and avidity assays in epitope screening campaigns.
- Analytics: Delivers quantitative particle size and purity data through DLS, NTA, and SDS-PAGE, enabling comparative analysis across constructs.
- Translational Research: Ensures structural continuity from E. coli-produced monomers to refolded nanoparticles, aligning with preclinical vaccine evaluation.
- Enterprise Reuse: Designed for adaptability across SAPN constructs and transferability to GMP manufacturing, supporting platform-based vaccine development.
Operational & Enterprise Impact
- Scientific Value: Provides predictive confidence in antigen presentation through trimeric display and reduced mechanistic ambiguity in immunogen design.
- Operational Value: Standardizes production via sonication, FPLC purification, isopropanol wash, and dialysis refolding, enhancing reproducibility.
- Strategic Value: Improves capital efficiency by enabling early-stage de-risking of vaccine candidates before costly preclinical investment.
- Portfolio Impact: Facilitates risk-adjusted prioritization of SAPN-based vaccines based on structural validation and endotoxin clearance.
Implementation Considerations
- Requires expertise in recombinant protein expression, FPLC operation, and dialysis-based refolding.
- Depends on access to sonicators, FPLC systems with nickel columns, DLS/NTA/TEM instruments, and stain-free SDS-PAGE equipment.
- Necessitates standardization of buffer compositions (imidazole-free, urea-containing, isopropanol wash) across teams for consistent results.
- Involves adaptation considerations for different SAPN constructs, particularly in optimizing elution gradients and refolding kinetics.
- Includes practical limitations such as potential aggregation during refolding and the need for endotoxin reduction beyond isopropanol wash for clinical use.
Biopharma FAQs
Why does endotoxin reduction matter for SAPN vaccine candidates?
The isopropanol wash step reduces residual bacterial lipopolysaccharide (LPS) to low levels, which is critical for minimizing inflammatory responses in vaccine formulations and supporting translational safety assessments.
How does FPLC purification enable isolation of six-helix bundle SAPNs?
FPLC using a nickel column separates the target protein based on histidine tag binding, allowing elution of SAPN monomers at specific imidazole concentrations and removal of contaminants through sequential wash steps.
What quantitative measurements confirm SAPN particle assembly and homogeneity?
Dynamic light scattering (DLS), nanoparticle tracking analysis (NTA), and transmission electron microscopy (TEM) are used to measure particle size distribution, confirming assembly in the 20–100 nm range and assessing polydispersity for batch consistency.
Why is refolding buffer composition critical for SAPN functionality?
The stepwise reduction of urea in the dialysis buffer, along with controlled pH, ionic strength, and reducing agents like TCEP, ensures proper folding and multimer assembly of the six-helix bundle SAPN into its native-like conformation.
How does Western blot analysis support SAPN identity and purity verification?
Western blot with anti-His and anti-167D4 antibodies confirms the presence of the target protein and its multimers in pooled fractions, enabling identification of pure SAPN preparations for downstream applications.
Chapters in this video
0:04
Title
0:43
Lysis of E. Coli BL21(DE3) Containing Six-Helix Bundle Self-assembling Protein Nanoparticles
1:24
Protein Purification
5:14
Purity Assessment and Protein Identification
6:28
SHB-SAPN Refolding
7:46
Dynamic Light Scattering (DLS)
8:30
Results: Representative SHB-SAPN Characterization
10:07
Conclusion
